Workflow
润都股份(002923) - 2025 Q1 - 季度财报
002923Rundu Pharma(002923)2025-04-28 17:50

Financial Performance - The company's revenue for Q1 2025 was ¥254,703,072.24, a decrease of 16.79% compared to ¥306,093,972.60 in the same period last year[5] - Net profit attributable to shareholders was ¥1,868,170.85, down 93.57% from ¥29,055,820.54 year-on-year[5] - The basic and diluted earnings per share dropped by 88.89% to ¥0.01 from ¥0.09 in the same period last year[5] - The company experienced a 90.46% decline in total profit, which amounted to ¥3,200,157.00 compared to ¥33,527,966.43 in the previous year, primarily due to policy impacts on formulation products[8] - Total comprehensive income attributable to the parent company was CNY 1,868,113.62, a decrease from CNY 29,056,328.01 in the previous period[18] - Net profit fell to ¥1.87 million compared to ¥29.06 million in the previous period, a decline of approximately 93.5%[17] Cash Flow and Liquidity - The net cash flow from operating activities increased by 4.93% to ¥23,916,914.54, compared to ¥22,794,035.25 in the previous year[5] - Cash inflow from operating activities totaled CNY 301,796,623.37, while cash outflow was CNY 277,879,708.83, resulting in a net cash inflow[18] - Cash flow from investing activities was negative at CNY -4,540,594.19, compared to CNY -55,794,033.20 in the previous period[19] - Cash inflow from financing activities was CNY 48,000,000.00, while cash outflow was CNY 69,460,930.77, leading to a net cash outflow of CNY -21,460,930.77[19] - The ending balance of cash and cash equivalents was CNY 175,573,870.47, down from CNY 196,412,733.73 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,187,546,987.06, a slight decrease of 0.28% from ¥2,193,636,977.65 at the end of the previous year[5] - Total liabilities decreased to ¥1.03 billion from ¥1.04 billion, a decline of about 0.9%[15] - Current liabilities totaled ¥496.36 million, down from ¥524.16 million, a decrease of approximately 5.3%[15] - Long-term borrowings increased to ¥382.46 million from ¥361.67 million, an increase of about 5.2% year-over-year[15] - The company reported a significant increase in expected liabilities by 39.76% to ¥2,637,715.68 due to increased provisions for hazardous waste costs[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,629[10] - The total number of shares held by the top two shareholders, Li Xi and Chen Xinmin, is 100,865,992 shares each, accounting for 60.24% of the total share capital at the end of the reporting period[11] - The top 10 shareholders include various institutional investors, with the largest being Li Xi and Chen Xinmin, both holding 30.12% each[11] - The company has a significant pledge situation, with Li Xi pledging 80,521,385 shares, which is approximately 79.8% of his total holdings[11] - There are no significant changes in the financing and securities lending activities of the top shareholders reported[11] Operational Metrics - Total operating revenue decreased to ¥254.70 million from ¥306.09 million, a decline of approximately 16.8% year-over-year[16] - Total operating costs reduced to ¥249.33 million from ¥273.58 million, reflecting a decrease of about 8.8% year-over-year[16] - Research and development expenses increased to ¥27.50 million from ¥24.95 million, representing an increase of about 10.2% year-over-year[16] - Total current assets increased to ¥905,332,383.62 from ¥885,753,509.84, showing a growth of about 2.93%[13] - Accounts receivable decreased from ¥138,011,657.35 to ¥132,542,849.01, indicating a reduction of about 3.39%[13] - Inventory rose to ¥455,508,538.34 from ¥442,008,841.36, representing an increase of approximately 3.05%[13] Future Outlook and Reporting - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[20] - The first quarter report was not audited, indicating preliminary financial results[20] - The company has not disclosed any new product developments or technological advancements during the reporting period[12] - The company has not reported any mergers or acquisitions in the current financial period[12]